Compass Pathways PLC Stock News

And other market news.

NEW YORK , March 2, 2022 /PRNewswire/ -- Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can''t be overstated. Indeed, the inability of the nervous system to change its activity in response to stimuli often produces stress-induced neuroplasticity, which plays a critical role in almost all mental disorders. The problem is conventional drugs have done little to correct damage in this response, resulting in mental health disorders that now affect nearly one in every eight people on the planet. Amazingly, research with psychedelic therapeutics has shown great promise, inspiring hope in treating a broad range of mental health disorders. With the urgent need for new, more effective treatments to treat a wide spectrum of disorders, Cybin Inc. (NEO: CYBN)(NYSE: CYBN )( Profile ) is pioneering groundbreaking research and striking important partnerships to unleash the power of these psychedelic-based compounds. Cybin has a differentiated method of progressing psychedelics into therapeutics than others in the sector, such as COMPASS Pathways Plc (NASDAQ: CMPS ), Mind Medicine Inc. (NASDAQ: MNMD ) (NEO: MMED), ATAI Life Sciences N.V . (NASDAQ: ATAI ) and GH Research PLC (NASDAQ: GHRS ), which are also intent on offering effective solutions.

GAINERS: Cybin (AMEX: CYBN ) shares closed up 4.25% at $0.94 Small Pharma (OTC: DMTTF ) shares closed up 1.43% at $0.23 Compass Pathways (NASDAQ: CMPS ) shares closed up 1.25% at $14.62 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 1.05% at $5.80 LOSERS: TripAdvisor (NASDAQ: TRIP ) shares … Full story available on Benzinga.com

CMPS earnings call for the period ending December 31, 2021.

GAINERS: Seelos Therapeutics (NASDAQ: SEEL ) shares closed up 11.06% at $1.10 Mind Medicine (NASDAQ: MNMD ) shares closed up 11.01% at $1.21 Compass Pathways (NASDAQ: CMPS ) shares closed up 4.50% at $13.23 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 3.83% at $5.42 Mindset Pharma (OTC: Full story available on Benzinga.com

COMPASS Pathways plc (NASDAQ: CMPS ) reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business. Q4 Financial Highlights Net loss totaled $25.7 million , or $0.61 loss per share, compared with $18.8 million, or $0.52 loss per share, during the same period in 2020. Research and development expenses were $13.6, compared with $4.5 million during the same period in 2020. General and administrative expenses were $14.7 million, compared with $7.0 million during the same period in 2020. 2021 Financial Highlights Net loss totaled 71.7 million, or $1.79 loss per share, compared with $60.3 million or $3.55 loss per share, … Full story available on Benzinga.com

COMPASS Pathways plc (CMPS) CEO George Goldsmith on Q4 2021 Results - Earnings Call Transcript

Related Stocks: SVFA , CCVI , CMPS , ROSS , PNM , FR , BCSAU , MEIP , BABA , HOOD , MOS , BTCM , HOV , GNLN , CFFE , AJRD , INKA , GOLD , RTPY , VHAQ , MBAC , CLAS , XOG , BSN ,

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022.

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in men

A new review study by Johns Hopkins University researchers is shedding light on the long-term effects of psilocybin in the treatment of major depression. In a new study, 58% of participants with major depressive disorder were in remission after one year of doing two sessions with psilocybin. “Psilocybin not only produces significant and immediate effects, it also has a long duration, which suggests that it may be a uniquely useful new treatment for depression,” said Roland Griffiths , Ph.D., Professor in Neuropsychopharmacology of Consciousness at Johns Hopkins School of Medicine. Psilocybin, also known as the active compound in “magic mushrooms,” is one of the compounds spearheading a pipeline that looks to advance psychedelic drugs for medical use. There are currently dozens of biotech companies developing psychedelic drugs for mental health indications. Compass Pathways (NASDAQ: CMPS ) is leading commercial research with … Full story available on Benzinga.com

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.